David P. Luci - Jun 29, 2021 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Kostantinos Skordalos, Power of Attorney For: David P. Luci
Stock symbol
ACXP
Transactions as of
Jun 29, 2021
Transactions value $
$0
Form type
4
Date filed
7/6/2021, 04:06 PM
Previous filing
Jun 24, 2021
Next filing
Nov 22, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACXP Stock Option Award $0 +350K $0.00 350K Jun 29, 2021 Common Stock 350K $6.26 Direct F1
transaction ACXP Stock Option Award $0 +500K $0.00 500K Jul 1, 2021 Common Stock 500K $6.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 29, 2021 (the "June Grant Date"), the Reporting Person was granted stock options to purchase 350,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.
F2 On July 1, 2021 (the "Employment Agreement Grant Date"), the Reporting Person was granted stock options to purchase 500,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's President and Chief Executive Officer pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024.

Remarks:

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.